Multiple Endocrine Neoplasia (MEN1) is an autosomal dominant disorder caused by alterations in the MEN1 gene. MEN1 is characterized by a broad spectrum of clinical manifestations, among which the three cardinal lesions are primary hyperparathyroidism, pituitary adenomas, and duodenal-pancreatic neuroendocrine tumors. Following the identification of the genetic predisposition, patients should be offered a program of combined clinical, biochemical and radiological screening, according to clinical practice guidelines published in 2012.
Since the identification of the MEN1 gene in 1997,the landscape of MEN1 diagnosis and disease has drastically improved, facilitating genetic counselling and allowing early diagnosis in patients with isolated lesions. Technological advances in medicine, including the universalization of “omics” technologies in the 2010s opened new perspectives for understanding the molecular mechanisms of the disease and refining the diagnosis.
In the era of personalized medicine, how do these elements allow us to improve the medical care of MEN1 patients?
In this Special Issue, " New insights into Multiple Endocrine Neoplasia type 1", we welcome investigators to contribute with original research and review articles to advance our knowledge in the molecular mechanisms of multiple endocrine neoplasia type 1, as well as to provide new insights on patient care. Ten years after the publication of clinical practice guidelines, we propose to showcase an update on applied clinical research on MEN1, including biological, genetic, and radiological diagnostic aspects, new therapeutic strategies, and evaluation of practices.
Multiple Endocrine Neoplasia (MEN1) is an autosomal dominant disorder caused by alterations in the MEN1 gene. MEN1 is characterized by a broad spectrum of clinical manifestations, among which the three cardinal lesions are primary hyperparathyroidism, pituitary adenomas, and duodenal-pancreatic neuroendocrine tumors. Following the identification of the genetic predisposition, patients should be offered a program of combined clinical, biochemical and radiological screening, according to clinical practice guidelines published in 2012.
Since the identification of the MEN1 gene in 1997,the landscape of MEN1 diagnosis and disease has drastically improved, facilitating genetic counselling and allowing early diagnosis in patients with isolated lesions. Technological advances in medicine, including the universalization of “omics” technologies in the 2010s opened new perspectives for understanding the molecular mechanisms of the disease and refining the diagnosis.
In the era of personalized medicine, how do these elements allow us to improve the medical care of MEN1 patients?
In this Special Issue, " New insights into Multiple Endocrine Neoplasia type 1", we welcome investigators to contribute with original research and review articles to advance our knowledge in the molecular mechanisms of multiple endocrine neoplasia type 1, as well as to provide new insights on patient care. Ten years after the publication of clinical practice guidelines, we propose to showcase an update on applied clinical research on MEN1, including biological, genetic, and radiological diagnostic aspects, new therapeutic strategies, and evaluation of practices.
